Oncolytics Biotech Inc. (ONCY) Stock Ticker
Market factors today
Unlock the full ONCY picture
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
ONCY stock facts
| Ticker symbol | ONCY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $68.6M |
| CEO | Jared Kelly |
| Employees | 29 |
| Headquarters | San Diego, CA, US |
| IPO date | 2001-10-05 |
| Website | www.oncolyticsbiotech.com |
What you can see for ONCY on Tickr
Live ONCY price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ONCY report.
Rankings
FAQ
What is the ticker symbol for Oncolytics Biotech Inc.?
The ticker symbol for Oncolytics Biotech Inc. is ONCY, listed on the NASDAQ.
What is ONCY?
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal…